{
  "metadata": {
    "case_id": 16,
    "model": "Gemini-3-Pro",
    "timestamp": "2025-11-28T06:01:31.051516",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/16_NCT04323800.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Gemini-3-Pro/16_Gemini-3-Pro.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.96,
          0.35
        ],
        [
          0.6,
          0.82
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "label": "High titer anti-SARS-CoV-2 plasma",
            "type": "EXPERIMENTAL",
            "description": "Participants with High titer anti-SARS-CoV-2 plasma.",
            "interventionNames": [
              "Biological: Anti- SARS-CoV-2 Plasma"
            ]
          },
          "pred_item": {
            "label": "CCP (COVID-19 Convalescent Plasma)",
            "type": "EXPERIMENTAL",
            "description": "Participants randomized to receive 1 unit of high titer (≥1:320) COVID-19 Convalescent Plasma.",
            "interventionNames": [
              "COVID-19 Convalescent Plasma"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.82,
          "status": "matched",
          "ref_item": {
            "label": "SARS-CoV-2 non-immune plasma",
            "type": "ACTIVE_COMPARATOR",
            "description": "Participants with SARS-CoV-2 non-immune plasma.",
            "interventionNames": [
              "Biological: SARS-CoV-2 non-immune Plasma"
            ]
          },
          "pred_item": {
            "label": "Control Plasma",
            "type": "PLACEBO_COMPARATOR",
            "description": "Participants randomized to receive 1 unit of standard SARS-CoV-2 non-immune control plasma.",
            "interventionNames": [
              "Control Plasma"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.98,
          0.4
        ],
        [
          0.65,
          0.98
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "type": "BIOLOGICAL",
            "name": "Anti- SARS-CoV-2 Plasma",
            "description": "SARS-CoV-2 convalescent plasma (1 unit; \\~200-250 mL collected by pheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320",
            "armGroupLabels": [
              "High titer anti-SARS-CoV-2 plasma"
            ]
          },
          "pred_item": {
            "type": "BIOLOGICAL",
            "name": "COVID-19 Convalescent Plasma",
            "description": "Plasma collected from donors with a history of SARS-CoV-2 infection and antibody levels ≥ 1:320 titer by Euroimmun ELISA.",
            "armGroupLabels": [
              "CCP (COVID-19 Convalescent Plasma)"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "type": "BIOLOGICAL",
            "name": "SARS-CoV-2 non-immune Plasma",
            "description": "Normal human plasma collected prior to December 2019",
            "armGroupLabels": [
              "SARS-CoV-2 non-immune plasma"
            ]
          },
          "pred_item": {
            "type": "BIOLOGICAL",
            "name": "Control Plasma",
            "description": "Standard SARS-CoV-2 non-immune plasma collected before January 1, 2020, or seronegative for SARS-CoV-2.",
            "armGroupLabels": [
              "Control Plasma"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 3,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.92
        ],
        [
          0.18
        ],
        [
          0.15
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.92,
          "status": "matched",
          "ref_item": {
            "measure": "Efficacy of Treatment at Day 28 as Assessed by Number of Participants Who Develop SARS-Cov-2 Infection",
            "description": "Comparison of proportions of cumulative incidence of development of SARS-Cov-2 infection (symptoms compatible with infection and/or + molecular testing) regardless of disease severity, following high-titer Anti- SARS-CoV-2 plasma versus control (SARS-CoV-2 non-immune plasma) in subjects exposed to COVID-19.",
            "timeFrame": "Day 28"
          },
          "pred_item": {
            "measure": "Incident SARS-CoV-2 infection",
            "description": "Defined by positive RT-PCR testing conducted on collected nasal swabs or by clinical RT-PCR testing conducted outside the study. Analyzed using restricted mean infection free time (RMIFT).",
            "timeFrame": "By study day 28"
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Safety of Treatment With High-titer Anti- SARS-CoV-2 Plasma Versus Control as Assessed by Number of Participants With \"Serious Adverse Events\"",
            "description": "Number of participants with serious adverse events categorized as either severe infusion reactions or Acute Respiratory Distress Syndrome during the study period.",
            "timeFrame": "Up to Day 28"
          },
          "pred_item": null
        },
        {
          "ref_idx": 2,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Safety of Treatment With High-titer Anti- SARS-CoV-2 Plasma Versus Control as Assessed by Cumulative Incidence of Grade 3 and 4 Adverse Events",
            "description": "Cumulative incidence of grade 3 and 4 adverse events during the study period evaluated as events per 100 person-years will be used to assess safety of the intervention.",
            "timeFrame": "Up to Day 28"
          },
          "pred_item": null
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 4,
      "similarity_matrix": [
        [
          0.86,
          0.55,
          0.3,
          0.3
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.86,
          "status": "matched",
          "ref_item": {
            "measure": "Number of Participants With Severe Disease",
            "description": "Number of participants with severe disease between the anti-SARS-CoV-2 convalescent plasma and control groups. Severity of disease will be measured using the number of participants with any of the disease severity categories below:\n\n1. Death\n2. Requiring mechanical ventilation and/or in ICU\n3. non-ICU hospitalization, requiring supplemental oxygen\n4. non-ICU hospitalization, not requiring supplemental oxygen",
            "timeFrame": "Up to 28 days"
          },
          "pred_item": {
            "measure": "Disease severity",
            "description": "Measured using a clinical event scale ranging from no infection to death, evaluated using an ordinal logistic model.",
            "timeFrame": "Up to day 28"
          }
        }
      ]
    }
  ]
}